RareResearch.AI
← Back to atlas

G656C

Category 5 — IDR ExclusionUncertain significanceLumenal · predictedσ-1 candidateSource card
GlycineCysteine at position 656 · C-terminal ER-lumenal (calcium binding, calmodulin, chaperone) · WFS1 (Wolframin)

Interactive 3D Structure

Wild-type reference
Wild-type G656 — hydrogen bond to R653
Fullscreen ↗
DynaMut2 mutant · G656C
Mutant C656 — polar contact contact to R653 lost
Fullscreen ↗

Bond changes · DynaMut2 interaction analysis

1 lost2 gained5 preserved
Interaction typeWild-type partnerMutant partnerStatus
Hydrogen bondR653R653Preserved
Hydrogen bondK658K658Preserved
Polar contactR653R653Preserved
Polar contactS654S654Preserved
Polar contactK658K658Preserved
Van der WaalsR653Gained
Van der WaalsS654Gained
Van der WaalsK658Lost

Lost / gained / preserved interatomic contacts at the variant residue, from the DynaMut2 (Arpeggio) interaction analysis of the wild-type and energy-minimized mutant structures.

Computational Predictions

DynaMut2 ΔΔG
-0.47kcal/mol
Destabilising — mild
AlphaMissense
0.946
likely pathogenic
AlphaFold pLDDT
49
model confidence
Schema
Cat 5
Category 5 — IDR Exclusion
ΔΔG confidence: Reduced confidence · Lumenal
  • pLDDT 48.88 below 70

The underlying AlphaFold model has pLDDT below 70 at this position, so the structure the stability calculation was run on is itself uncertain.

Do not rank this value against a variant from a different region on ΔΔG alone.

Clinical Evidence

ClinVar classificationUncertain significance
Review statuscriteria provided, single submitter
Associated conditions
Population frequency (gnomAD v4)Ultra-rare · AF 0.00014%
cDNA changec.1966G>T
ClinVar accessionVCV004802688
Last evaluated2025/05/24 00:00

Observed at very low frequency in gnomAD.

Classified for1★ unverified submission

ClinVar classifies this variant as Uncertain significance, but does not state what it is classified for. ClinVar records no condition for this variant. A classification without a phenotype and an inheritance mode cannot be read as a statement about Wolfram syndrome risk or severity.

  • Phenotype scope is interpretation of submitted records. The computed values on this card (AlphaMissense, DynaMut2 ΔΔG, pLDDT) are measurements of the model, not of a patient.
  • Presentation cannot be generalised from neighbouring variants: one nucleotide over can present very differently. Structural similarity supports a mechanistic hypothesis, never a phenotype claim.

Review status: 1★ single submitter. ClinVar "conditions" is the union of all submissions; 0–1★ entries are submitted conditions, not documented phenotypes.

Population frequency
Global (all ancestries)
AF 0.00014% · 2 / 1,461,378 alleles
Homozygotes
0
Highest-frequency population
European (non-Finnish) · AF 0.00018%

Highest in European (non-Finnish): AF 0.00018% (2 of 1,112,006 alleles), in line with the global figure.

No homozygotes reported in gnomAD v4. For a recessive allele this is expected and is not, on its own, evidence either way.

Ancestry groupAllele freq.AC / ANHom.Carrier est.
European (non-Finnish)0.00018%2 / 1,112,0060~1 in 278000

Source: gnomAD r4, retrieved 2026-08-21. Values are allele frequencies. The carrier estimate is derived from the allele frequency (Hardy-Weinberg, ~2·AF) and is an approximation, not a published figure — where a published carrier frequency exists it outranks this column and is cited on the card.

Full Variant Card

WFS1 Wolframin — G656C Variant Card

Molecular Atlas Pilot · RareResearch.AI · Generated by wolfram-variant-card skill

Glycine → Cysteine at position 656. C-terminal ER-lumenal (calcium binding. ClinVar Uncertain significance, AlphaMissense 0.946, DynaMut2 ΔΔG -0.47 kcal/mol (destabilising).


Identity

FieldValue
VariantG656C (p.Glycine656Cysteine)
DNA changec.1966G>T
Gene · ProteinWFS1 · Wolframin (890 aa)
UniProtO76024 · WFS1_HUMAN
ClinVar accessionVCV004802688
Amino acid changeGlycine (G) → Cysteine (C)

Structural Context

FieldValue
AlphaFold modelAF-O76024-F1, v6
pLDDT at residue 65648.88IDR (below 50 threshold)
DomainC-terminal ER-lumenal (calcium binding, calmodulin, chaperone)
Position contextC-terminal lumenal domain · position 656 projects into the ER lumen
IDR flagYES — pLDDT below 50 (Cat 5)

UniProt features at this position:

(none catalogued)

Position 656 sits in the C-terminal lumenal domain (residues 653–869), wolframin's largest soluble region. This domain projects into the ER lumen and is implicated in calcium handling, ER stress sensing, and protein–protein interactions with ATF6 and Na+/K+ ATPase β1. The wild-type residue is small/flexible (glycine — backbone flexibility, no sidechain); the mutant is thiol (cysteine — disulfide-capable, free -SH). The chemistry shift implies altered local packing, hydrogen-bonding, and/or electrostatics at this site.


Computational Predictions

AlphaMissense

FieldValue
am_pathogenicity0.9461
am_classlikely pathogenic
InterpretationLikely pathogenic (threshold 0.564)

DynaMut2

FieldValue
ΔΔG (kcal/mol)-0.47 (Destabilising)
Job ID178092141279
Result URLJob 178092141279 · retrieved 2026-06-08 — result self-hosted by RareResearch.AI (Biosig no longer serves this page)

Clinical Evidence

Inheritance and scope

Uncertain significance — phenotype scope not stated in ClinVar

ClinVar classifies this variant as Uncertain significance, but does not state what it is classified for. ClinVar records no condition for this variant. A classification without a phenotype and an inheritance mode cannot be read as a statement about Wolfram syndrome risk or severity.

Phenotype scope is interpretation of submitted records. The computed values on this card (AlphaMissense, DynaMut2 ΔΔG, pLDDT) are measurements of the model, not of a patient. Presentation cannot be generalised from neighbouring variants: one nucleotide over can present very differently. Structural similarity supports a mechanistic hypothesis, never a phenotype claim.

FieldValue
ClassificationUncertain significance
Review statuscriteria provided, single submitter
Last evaluated2025/05/24 00:00
InheritanceInheritance pattern not specified in ClinVar entry; WFS1 has both AD and AR presentations.
WFS1 variant landscapeG656C is 1 of ~326 pathogenic-spectrum variants in WFS1 (out of 2,243 catalogued in ClinVar)

(no conditions catalogued)


Research Path Decision Tree

ΔΔG < 2  + binding site affected   →  CATEGORY 3 — docking experiments
ΔΔG 2–4                            →  CATEGORY 2 — pharmacological chaperones
ΔΔG > 4                            →  CATEGORY 1 — gene therapy
pLDDT < 50                         →  CATEGORY 5 — IDR, experimental only
Stable fold + functional site hit  →  CATEGORY 4 — site-specific docking

Final Schema Categorization

Category 5 — IDR Exclusion

<strong>Category 5 — IDR Exclusion</strong><br/><br/>pLDDT 48.88 is below 50; DynaMut2 result not trustworthy. Route to wet-lab.

Why this card matters. Position sits in a low-confidence region. Computational stability estimates here are unreliable; this variant needs experimental characterization before any therapeutic strategy is set.


Files in this folder

  • AF-O76024-F1-model_v6.pdb — AlphaFold structure
  • G656C_molstar_viewer.html — interactive 3D viewer (auto-highlights position 656 with ball-and-stick + neighbors within 5Å)
  • G656C_variant_card.md — this card (source of truth)
  • G656C_variant_card.html — styled printable card
  • G656C_dynamut2_summary.html — clean offline DynaMut2 result card
  • dynamut2_result.json — structured result data
  • dynamut2_result_page.html — local snapshot of the Biosig result page (asset URLs absolutized)
  • G656C_wildtype_interactions.pse / G656C_mutant_interactions.pse — PyMOL sessions

Generated by wolfram-variant-card skill · RareResearch.AI Molecular Atlas Every assumption documented. Every score sourced.

Therapeutic Strategy Handoff · prediction

Feed this card to Wolfram Intelligence

Download the G656C PDF below and upload it to Wolfram Intelligence to generate therapeutic-strategy proposals — guanidinium mimetics, sigma-1 agonist docking, NAC thiol-capping. NAC is already on the bench-testing list.

Download G656C PDF card ↓Strategies are AI-generated predictions, not validated therapeutics.